COMPARISON OF CARVEDILOL AND BISOPROLOL EFFICACY IN PATIENTS WITH CHRONIC HEART FAILURE AND DIABETES TYPES 2 AFTER MYOCARDIAL INFARCTION
https://doi.org/10.20996/1819-6446-2008-4-2-30-33
Abstract
Aim. To compare efficacy of carvedilol and bisoprolol in patients with chronic heart failure (CHF) and diabetes mellitus (DM) type 2 after myocardial infarction (MI).
Material and methods. 60 patients (45-70 y.o.) with CHF 2-3 functional class according to NYHA and DM type 2 after MI (3-4 week) are included in the study. Patients are randomized on 2 groups. All patients received basic therapy of CHF. Besides patients of 1st group (n=30) were treated with carvedilol (Talliton, Egis) 29,0±2,5 mg daily. Patients of 2nd group (n=30) were treated with bisoprolol (6,0±0,5 mg/day). Both groups were similar on age, sex, disease severity, haemodynamic parameters and basic therapy doses. Life quality, functional reserve, echocardiography, kidney function, heart rate variability (HRV), lipid and glucose metabolism were estimated initially and in 16 weeks of treatment.
Results. Carvedilol and bisoprolol therapy of patients with CHF and DM after MI resulted in improvement of clinical status, kidney function and increase in HRV. Carvedilol had clinical advantages in comparison with bisoprolol in effects on myocardial remodeling, kidney function and HRV. Carvedilol favorable effects on lipid and glucose metabolism were observed.
Conclusion. Carvedilol has a number of significant advantages in comparison with bisoprolol in the therapy of patients with CHF and DM after MI.
About the Authors
M. E. Statsenko
Volgograd State Medical University, Chair of Internal Medicine
City Сlinical Hospital № 3
Russian Federation
Russian Federation
S. V. Belenkova
Volgograd State Medical University, Chair of Internal Medicine
City Сlinical Hospital № 3
Russian Federation
Russian Federation
O. E. Sporova
Volgograd State Medical University, Chair of Internal Medicine
City Сlinical Hospital № 3
Russian Federation
Russian Federation
D. A. Ivanova
Volgograd State Medical University, Chair of Internal Medicine
City Сlinical Hospital № 3
Russian Federation
Russian Federation
E. D. Evtereva
Volgograd State Medical University, Chair of Internal Medicine
City Сlinical Hospital № 3
Russian Federation
Russian Federation
References
1. Беленков Ю.Н., Мареев В.Ю. Принципы рационального лечения сердечной недостаточности. М.: Медиа Медика; 2000.
2. Дедов И.И., Шестакова М.В., Максимова М.А. Федеральная целевая программа «Сахарный диабет». Методические рекомендации. М.: Медиа Сфера; 2002.
3. Дедов И.И., Шестакова М.В. Диабетическая нефропатия. М.: Универсум Паблишинг; 2000.
4. Джахангиров Т.Ш. Сердечная недостаточность и сахарный диабет: распространенность, заболеваемость и прогноз. Сердечная недостаточность 2005; 6(3): 35-8.
5. Закирова А.Н., Габидуллин Р.Р., Закирова Н.Э. Клинико-гемодинамические эффекты карведилола, влияние на перекисное окисление липидов и маркеры воспаления у больных ИБС с ХСН. Сердечная недостаточность 2006;7(1):1-3.
6. Ситникова М.Ю, Большакова О.О., Вахрамеева Н.В. и др. Эндотелиальная дисфункция и состояние перекисного окисления липидов у больных хронической сердечной недостаточностью. Влияние длительной терапии карведилолом. Росс кардиол журн 2001;6(32):48-54.
7. Соколов Е.И. Диабетическое сердце. М.: Медицина; 2002.
8. Хирманов В.Н. Факторы риска: микроальбуминурия. Тер арх 2004;(9):78- 84.
9. Шальнова С.А., Деев А.Д, Оганов Р.Г. Факторы, влияющие на смертность от сердечно-сосудистых заболеваний в российской популяции. Кардиова- скулярная терапия и профилактика 2005;(1):4-9.
10. Национальные рекомендации ВНОК и ОССН по диагностике и лечению ХСН (второй пересмотр). Журнал Сердечная недостаточность 2007;8(2):1-35.
11. Решетько О.В. Инновационные лекарственные средства для лечения сер- дечной недостаточности: взгляд в будущее. Качественная клиническая прак- тика 2003;2:2-10
12. Stroe A.F., Gheorgiade M. Carvedilol: b-blockade and beyond. Rev Cardiovasc Med 2004; 5 (Suppl 1):S18-27.
13. Bacris G.L., Fonseca V., Katholi R.E. et al. GEMINI Ivestigators. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 2004; 292(18):2227-36.
14. Bauters C., Lamblin N., Mc Fadden E.P. et al. Influence of diabetes mellitus on heart failure risk and outcome. Cardiovascular Diabetol 2003;2:1.
15. Bell D.S. Heart failure: the frequent, forgotten, and often fatal complication of diabetes. Diabetes Care 2003; 26(8): 2433-441.
16. Calo L.A., Semplicini A., Davis P.A. Antioxidant and anti-inflammatory effect of carvedilol in mononuclear cells of hypertensive patients. Am J Med 2005;118(2):201-2.
17. Chen Y.T., Vaccarino V., Williams C.S. et al. Risk factors for heart failure in the elderly: a prospective community-based study. Am J Med 1999;106(6):605- 12.
18. Giugliano D, Acampora R, Marfella R, et al. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin dependent diabetes mellitus and hypertension. A randomised controlled trial. Ann Intern Med 1997;126(12):955- 59.
19. Goto Y. Effects of alfa- and beta-blocker antihypertensive therapy on blood lipids: a multicenter trial. Am J Med 1984;76(2A):72-8.
20. Haas S.J., Vos T., Gilbert R.E., Krum H. Are beta-blockers as efficacious in patients with dia-betes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials. Am Heart J 2003;146(5):848-53.
21. He J., Ogden L.G., Bazzano L.A., et al. Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. Arch Intern Med 2001;161(7):996-1002.
22. Jakob S., Rett K., Wicklmayr M. et al. Differential effect of chronic treatment with two betablocking agents on insulin sensitivity: the carvedilol-metoprolol study. J Hypertens 1996;14(4):489-94.
23. Kannel W.B., McGee D.L. Diabetes and cardiovascular disease: the Framingham study. JAMA 1979;241(19):2035-8.
24. Oliveira P.J., Esteves T., Rolo A.P. et al. Carvedilol inhibits the mitochondrial permeability trasition by an antioxidant mechanism. Cardiovasc Toxicol 2004;4:11- 20.
25. Singh D, Chander V., Chopra K. Carvedilol, an antihypertensive drug with antioxidant properties, protects against glycerol-induced acute renal failure. Am J Nephrol 2003;23(6): 415-21.
Review
For citations:
Statsenko M.E., Belenkova S.V., Sporova O.E., Ivanova D.A., Evtereva E.D. COMPARISON OF CARVEDILOL AND BISOPROLOL EFFICACY IN PATIENTS WITH CHRONIC HEART FAILURE AND DIABETES TYPES 2 AFTER MYOCARDIAL INFARCTION. Rational Pharmacotherapy in Cardiology. 2008;4(2):30-33. (In Russ.) https://doi.org/10.20996/1819-6446-2008-4-2-30-33
Views:
2595
Email this article 